HIV in Europe started in Brussels in 2007 with a pan-European conference entitled “HIV in Europe 2007: Working together for optimal testing and earlier care". The conference gathered more than 300 key European stakeholders in HIV from the Europe WHO region, including advocates, clinicians and public health professionals. In November 2009, a Follow-Up meeting in Stockholm was held under the Swedish Presidency of the European Union.
The initiative provides a European platform for exchange and activities to improve early diagnosis and care of people living with HIV and viral hepatitis across Europe. Directed by an extensive and independent group of experts with representation from civil society, policy makers, health professionals and European public health institutions, the initiative is truly a multi-disciplinary and pan-European collaboration.
HIV in Europe is an initiative formed to inform policy-making/implementation, knowledge sharing, and to improve the evidence base on important issues related to earlier HIV testing and care. It is unique in its collaboration between stakeholders from both clinical, advocacy and public health policy levels, who all share the common objective of ensuring that people living with HIV and viral hepatitis enter care earlier in the course of their infection.
The work of HIV in Europe has been made possible by unrestricted funding provided by Gilead Sciences, Merck, Tibotec, Pfizer, Schering-Plough, Abbott, Boehringer Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare, the Swedish Research Council, and the European Union’s Health Programme. Industry sponsors are invited to quarterly updates but do not participate in steering committee meetings
The initiative is governed by an independent Steering Committee.
Coordinating Centre, Rigshospitalet, University of Copenhagen
Policy Secretariat, EATG
Financial Administration, AIDS Fonds Netherlands.
The HIV in Europe initiative will continue to work for a strengtened collaboration in order to improve the evidence base to address important issues around earlier testing and optimal care and to find ways to share knowledge and experiences across European borders.